deCODE genetics

Olink enters into an agreement with deCODE genetics for early access to the Olink Explore 3072 Platform

Retrieved on: 
Tuesday, July 13, 2021
deCODE genetics, Decoding, Genomics

Through an agreement between the two companies, deCODE genetics will be one of the first companies to adopt and internalize the new Explore 3072 proteomics platform and will act as an early testing site for its use.

Key Points: 
  • Through an agreement between the two companies, deCODE genetics will be one of the first companies to adopt and internalize the new Explore 3072 proteomics platform and will act as an early testing site for its use.
  • We are proud to work closely with deCODE genetics world-class genomic and pharmaceutical scientists, said Jon Heimer, CEO of Olink.
  • We see deCODE genetics as an exceptional early-access site for the Olink Explore 3072 platform.
  • Olink intends to make the Olink Explore 3072 high quality protein assay platform broadly available in the fourth quarter of 2021.

nference and Mayo Clinic Study Confirms Link Between Anemia and Rehospitalization After COVID-19 Infection Clearance

Retrieved on: 
Monday, July 12, 2021
Coronaviridae, Sarbecovirus, Zoonoses, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome, deCODE genetics

Authors of the study, " Anemia during SARS-CoV-2 infection is associated with rehospitalization after viral clearance ," found that pre-COVID-19 anemia is the strongest clinical signature of long-term COVID-19 phenotypes, and can appear weeks or months after a COVID-19 infection has been cleared from a patient's immune system.

Key Points: 
  • Authors of the study, " Anemia during SARS-CoV-2 infection is associated with rehospitalization after viral clearance ," found that pre-COVID-19 anemia is the strongest clinical signature of long-term COVID-19 phenotypes, and can appear weeks or months after a COVID-19 infection has been cleared from a patient's immune system.
  • By analyzing lab test results for patients rehospitalized after a COVID-19 infection, nference and Mayo Clinic researchers found that patients rehospitalized as a result of long-term COVID-19 symptoms are more likely to have experienced anemia before their diagnosis and during the time they were infected with COVID-19.
  • "This is an excellent demonstration of how nference triangulates various data sets to decode the natural history of diseases," said Venky Soundararajan, PhD, co-founder and chief scientific officer of nference.
  • Through its powerful augmented intelligence software nferX, nference is transforming health care by making biomedical knowledge computable.

FortressIQ Launches FortressIQ Academy to Bring Hands-On Training to Customers and Partners

Retrieved on: 
Wednesday, June 23, 2021
Classes of computers, Technology, Companies, Lightspeed Venture Partners, deCODE genetics, Business process management, ENIAC, Workflow, Comcast

SAN FRANCISCO, June 23, 2021 (GLOBE NEWSWIRE) -- FortressIQ , the company delivering end-to-end process insights for the modern enterprise, this week announced the launch of FortressIQ Academy.

Key Points: 
  • SAN FRANCISCO, June 23, 2021 (GLOBE NEWSWIRE) -- FortressIQ , the company delivering end-to-end process insights for the modern enterprise, this week announced the launch of FortressIQ Academy.
  • FortressIQ Academy provides efficient, hands-on training with phased programs for learners of all levels.
  • FortressIQ enables enterprises to decode work, transform experiences, and enhance workflows with the industrys most advanced process intelligence platform.
  • FortressIQ was founded in 2017, and is backed by Lightspeed Venture Partners, Boldstart Ventures, Comcast Ventures, Eniac Ventures, M12 and Tiger Global.

PhysIQ Adds NorthShore University HealthSystem to COVID-19 Digital Biomarker Study

Retrieved on: 
Tuesday, June 15, 2021
Research, Other Health, Pharmaceutical, Medical devices, Infectious diseases, Hospitals, Clinical trials, Science, Cardiology, Biotechnology, Nursing, FDA, Health, Biology, Biomarkers, Branches of biology, Life sciences, Biotechnology, Evanston, Illinois, Highland Park, Illinois, NorthShore University HealthSystem, Skokie, Illinois, deCODE genetics, North Shore, COVID-19, physIQ, NorthShore University HealthSystem, PHYSIQ, NORTHSHORE UNIVERSITY HEALTHSYSTEM

NorthShore University HealthSystem (NorthShore) has joined physIQ s NIH-funded DeCODe study to develop an AI-based COVID-19 digital biomarker.

Key Points: 
  • NorthShore University HealthSystem (NorthShore) has joined physIQ s NIH-funded DeCODe study to develop an AI-based COVID-19 digital biomarker.
  • NorthShore will serve as an enrollment center and key partner in the Phase II validation stage of this study.
  • Using continuous multi-parameter vital signs and physiological features, we hope to support physIQ in establishing a targeted COVID-19 digital biomarker to help detect worsening patients.
  • Adding NorthShore as a site brings new dimension to the study that will be extremely valuable to the study outcomes.

deCODE genetics - Rounding off the human genome

Retrieved on: 
Monday, May 10, 2021
Branches of biology, Biology, Genetics, Biotechnology, Molecular biology, Genomics, DNA, deCODE genetics, Whole genome sequencing, Read, Third-generation sequencing, Structural variation

However of 133,886 reliably genotyped structural variants detected with long-read sequencing only 60% can be detected with short-reads.\nUsing PromethION sequencers from Oxford Nanopore Technologies, researchers at deCODE genetics whole genome sequenced 3,622 Icelanders.

Key Points: 
  • However of 133,886 reliably genotyped structural variants detected with long-read sequencing only 60% can be detected with short-reads.\nUsing PromethION sequencers from Oxford Nanopore Technologies, researchers at deCODE genetics whole genome sequenced 3,622 Icelanders.
  • These variants were then imputed into a larger set of participants in various disease studies at deCODE genetics and associated with phenotypes.
  • This is a major stumbling block in the attempt to fully understand the relationship between variation in the sequence of the human genome and human diversity.
  • Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases.

deCODE genetics - Rounding off the human genome

Retrieved on: 
Monday, May 10, 2021
Branches of biology, Biology, Genetics, Biotechnology, Molecular biology, Genomics, DNA, deCODE genetics, Whole genome sequencing, Read, Third-generation sequencing, Structural variation

However of 133,886 reliably genotyped structural variants detected with long-read sequencing only 60% can be detected with short-reads.\nUsing PromethION sequencers from Oxford Nanopore Technologies, researchers at deCODE genetics whole genome sequenced 3,622 Icelanders.

Key Points: 
  • However of 133,886 reliably genotyped structural variants detected with long-read sequencing only 60% can be detected with short-reads.\nUsing PromethION sequencers from Oxford Nanopore Technologies, researchers at deCODE genetics whole genome sequenced 3,622 Icelanders.
  • These variants were then imputed into a larger set of participants in various disease studies at deCODE genetics and associated with phenotypes.
  • This is a major stumbling block in the attempt to fully understand the relationship between variation in the sequence of the human genome and human diversity.
  • Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases.

Define AI Strategies to Advance Patient Centricity & Business Outcomes at Decode: AI for Pharmaceuticals Forum

Retrieved on: 
Thursday, April 1, 2021
Pharma, deCODE genetics

In spite of these recent advances, pharmaceutical organizations still have a long way to go in order to achieve true, scalable AI for maximum gains.

Key Points: 
  • In spite of these recent advances, pharmaceutical organizations still have a long way to go in order to achieve true, scalable AI for maximum gains.
  • Running from Monday June 7 Wednesday June 9, 2021, the Decode: AI for Pharma Forum serves to fill a gap in the conference landscape for an event that combines technology innovation with the needs and business goals of pharmaceutical companies.
  • Our portfolio of events focuses on technology fields where research and development are essential for the advancement of innovation.
  • We pride ourselves on providing the platforms where communities can Research, Collaborate, to achieve Advancement.

PhysIQ Saw Significant Adoption of Their AI Technology in 2020

Retrieved on: 
Thursday, January 28, 2021
FDA, Biotechnology, Health, Defense, Security, Other Professional Services, Consulting, Other Philanthropy, Professional services, Other Education, Other Science, Philanthropy, Continuing, Research, University, Other Technology, Other Defense, Contracts, Education, Managed care, Software, Other Consumer, General Health, Networks, Internet, Women, Seniors, Data management, MEN, Mobile, Wireless, Technology, Other Health, Consumer, Small business, Pharmaceutical, Oncology, Medical devices, Infectious diseases, Hospitals, Fund Raising, Science, Nursing, Clinical trials, Cardiology, Occupational safety and health, Coronavirus disease, Zoonoses, deCODE genetics, Health, Branches of biology, Articles

PhysIQ, Inc. will mark 2020 as a very important year-to-date for the leader in furthering acceptance and adoption of its digital medicine platform.

Key Points: 
  • PhysIQ, Inc. will mark 2020 as a very important year-to-date for the leader in furthering acceptance and adoption of its digital medicine platform.
  • Our entire healthcare infrastructure continues to be strained by COVID-19 and technology has become a growing factor in not only this fight but across healthcare, said Gary Conkright, CEO of physIQ.
  • In September 2020, The National Institutes of Health (NIH) awarded a contract to physIQ to develop an AI-based COVID-19 digital biomarker to address the rapid decline of high-risk COVID-19 patients.
  • In just 10 weeks, physIQ successfully enrolled and monitored 400 high-risk COVID-19 patients in Phase I of the DeCODe study .

deCODE genetics: Monozygous but not identical

Retrieved on: 
Thursday, January 7, 2021
Branches of biology, Biology, Sibling, Twin, Zoology, Genetics, deCODE genetics, Gene

In the study of human genetics the genomes of monozygotic twins are often assumed to be identical, and differences between them have been pinned on the environment ratherthan genetics.

Key Points: 
  • In the study of human genetics the genomes of monozygotic twins are often assumed to be identical, and differences between them have been pinned on the environment ratherthan genetics.
  • This assumption has been used throughout the centuries to disentangle the contribution of genetics and environment to disease and other phenotypes.
  • Hkon Jnsson and colleagues sequenced the genomes of 387 pairs of identical twins and their parents, spouses and children to track mutation divergence.
  • Thora Kristin Asgeirsdottir, PR and Communications deCODE genetics, 00354 -570 1909, 00354 -894 1909, [email protected]
    View original content to download multimedia: http://www.prnewswire.com/news-releases/decode-genetics-monozygous-but-n...

deCODE genetics: Monozygous but not identical

Retrieved on: 
Thursday, January 7, 2021
Branches of biology, Biology, Sibling, Twin, Zoology, Genetics, deCODE genetics, Gene, Mutation

In the study of human genetics the genomes of monozygotic twins are often assumed to be identical, and differences between them have been pinned on the environment ratherthan genetics.

Key Points: 
  • In the study of human genetics the genomes of monozygotic twins are often assumed to be identical, and differences between them have been pinned on the environment ratherthan genetics.
  • This assumption has been used throughout the centuries to disentangle the contribution of genetics and environment to disease and other phenotypes.
  • Hkon Jnsson and colleagues sequenced the genomes of 387 pairs of identical twins and their parents, spouses and children to track mutation divergence.
  • Thora Kristin Asgeirsdottir, PR and Communications deCODE genetics, 00354 -570 1909, 00354 -894 1909, [email protected]